Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
SLRX - Salarius Pharmaceuticals, Inc.
Market Cap 3.17M P/E - EPS this Y 86.80% Ern Qtrly Grth -
Income -6.46M Forward P/E -0.20 EPS next Y -127.00% 50D Avg Chg -30.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -49.00%
Dividend N/A Price/Book 0.42 EPS next 5Y - 52W High Chg -87.00%
Recommedations 3.00 Quick Ratio 2.78 Shares Outstanding 1.44M 52W Low Chg 15.00%
Insider Own 2.52% ROA -53.99% Shares Float 1.40M Beta 0.96
Inst Own 1.81% ROE -119.83% Shares Shorted/Prior 9.40K/42.52K Price 0.95
Gross Margin - Profit Margin - Avg. Volume 111,506 Target Price 26.00
Oper. Margin - Earnings Date Nov 7 Volume 35,692 Change 7.12%
Healthcare | Biotechnology | United States
About Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.

Salarius Pharmaceuticals, Inc. News
11/14/24 Salarius: Q3 Earnings Snapshot
08/09/24 Salarius: Q2 Earnings Snapshot
07/11/24 Sector Update: Health Care Stocks Rise Late Afternoon
06/17/24 Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with MDS and CMML Presented at the 2024 European Hematology Association Annual Meeting
06/12/24 Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split
04/02/24 SLRX Pursues Important Goal
03:05 PM Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
08:00 AM Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses
01/16/24 Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders
01/03/24 Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Burleson Tess Director Director Jun 07 Buy 0.18 27,700 4,986 32,050 06/08/22
Lieber Jonathan I Director Director Jun 07 Buy 0.1871 37,500 7,016 37,500 06/08/22
HANISH ARNOLD C Director Director Jun 03 Buy 0.184 28,000 5,152 46,350 06/06/22
HANISH ARNOLD C Director Director Aug 21 Buy 0.98 4,000 3,920 11,350 06/06/22
HANISH ARNOLD C Director Director Feb 11 Buy 1.15 4,350 5,002 7,350 06/06/22
HANISH ARNOLD C Director Director Nov 25 Buy 3.59 3,000 10,770 3,000 06/06/22
Arthur David J. Chief Executive Offi.. Chief Executive Officer May 26 Buy 0.18 43,900 7,902 303,574 05/31/22
Rosenblum Mark J Exec VP Finance, CFO Exec VP Finance, CFO May 31 Buy 0.18 28,000 5,040 148,319 05/31/22
Rosenblum Mark J Exec VP Finance, CFO Exec VP Finance, CFO Mar 03 Buy 0.391 76,246 29,812 110,319 03/09/22
Arthur David J. Chief Executive Offi.. Chief Executive Officer Mar 03 Buy 0.391 139,488 54,540 249,674 03/09/22